Evidence map›Paper›PMID 30810064›Full record

ArticleAmerican journal of physiology. Renal physiology2019

A dual blocker of endothelin A/B receptors mitigates hypertension but not renal dysfunction in a rat model of chronic kidney disease and sleep apnea.

Humberto Morales-Loredo, David Jones, Adelaeda Barrera, Perenkita J Mendiola, Joshua Garcia, Carolyn Pace, Minerva Murphy, Nancy L Kanagy, Laura V Gonzalez Bosc

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of physiology. Renal physiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. American journal of physiology. Renal physiology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Humberto Morales-LoredoVascular Physiology Group, Department of Cell Biology and Physiology, University of New Mexico Health Sciences Center , Albuquerque, New Mexico.
David JonesVascular Physiology Group, Department of Cell Biology and Physiology, University of New Mexico Health Sciences Center , Albuquerque, New Mexico.
Adelaeda BarreraVascular Physiology Group, Department of Cell Biology and Physiology, University of New Mexico Health Sciences Center , Albuquerque, New Mexico.
Perenkita J MendiolaVascular Physiology Group, Department of Cell Biology and Physiology, University of New Mexico Health Sciences Center , Albuquerque, New Mexico.
Joshua GarciaVascular Physiology Group, Department of Cell Biology and Physiology, University of New Mexico Health Sciences Center , Albuquerque, New Mexico.
Carolyn PaceVascular Physiology Group, Department of Cell Biology and Physiology, University of New Mexico Health Sciences Center , Albuquerque, New Mexico.
Minerva MurphyVascular Physiology Group, Department of Cell Biology and Physiology, University of New Mexico Health Sciences Center , Albuquerque, New Mexico.
Nancy L KanagyVascular Physiology Group, Department of Cell Biology and Physiology, University of New Mexico Health Sciences Center , Albuquerque, New Mexico.
Laura V Gonzalez BoscVascular Physiology Group, Department of Cell Biology and Physiology, University of New Mexico Health Sciences Center , Albuquerque, New Mexico.
University of New Mexico · US

Funding

MINORITY INSTITUTIONAL RESEARCH TRAINING PROGRAM (T32)T32HL007736 · NHLBI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI RESTA, THOMAS C · 1993 to 2025
$6.5M
Hydrogen sulfide regulation of vascular tone and blood pressureR01HL123301 · NHLBI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI KANAGY, NANCY L · 2015 to 2018
$1.5M
NHLBI NIH HHS R01 HL123301NHLBI NIH HHS T32 HL007736
6 · The paper itself

Abstract

Obstructive sleep apnea is characterized by recurrent episodes of pharyngeal collapse during sleep, resulting in intermittent hypoxia (IH), and is associated with a high incidence of hypertension and accelerated renal failure. In rodents, endothelin (ET)-1 contributes to IH-induced hypertension, and ET-1 levels inversely correlate with glomerular filtration rate in patients with end-stage chronic kidney disease (CKD). Therefore, we hypothesized that a dual ET receptor antagonist, macitentan (Actelion Pharmaceuticals), will attenuate and reverse hypertension and renal dysfunction in a rat model of combined IH and CKD. Male Sprague-Dawley rats received one of three diets (control, 0.2% adenine, and 0.2% adenine + 30 mg·kg

Indexed as

AnimalsAntihypertensive AgentsArterial PressureDisease Models, AnimalEndothelin-1Endothelin A Receptor AntagonistsEndothelin B Receptor AntagonistsGlomerular Filtration RateHypertensionKidneyMalePyrimidinesRats, Sprague-DawleyRenal Insufficiency, ChronicSleep Apnea SyndromesSulfonamidesAntihypertensive AgentsEndothelin-1Endothelin A Receptor AntagonistsEndothelin B Receptor AntagonistsmacitentanPyrimidinesSulfonamideschronic kidney diseaseendothelinintermittent hypoxiamacitentanobstructive sleep apnea

Identifiers

PMID30810064
PMCPMC7132313
OpenAlexW2918074187

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.